Group 1 - The sixth Panoramic Investor Relations Gold Award was recently announced, with Jiukang Biological (300406.SZ) winning the "Outstanding IR Team" award and its Secretary Wang Jianmin receiving the "Outstanding Secretary" award [1] - The evaluation process involved self-nomination, public online voting, professional index scoring, and expert review, covering thousands of A-share companies, establishing itself as a benchmark in the capital market IR field [1] - The award focuses on six innovative dimensions: digital investor relations, response to small investors' concerns, institutional attention, market value management, shareholder returns, and ESG value dissemination, marking Jiukang Biological's IR management as recognized by the capital market [1] Group 2 - Jiukang Biological has been a leader in the domestic in vitro diagnostic industry for 20 years, developing a diversified and high-quality diagnostic testing platform [2] - The company has established various biochemical research and development platforms, including chemical methods, enzyme methods, and immunoassay techniques, and has high-level R&D capabilities in liquid blood coagulation and blood type testing [2] - Jiukang Biological's subsidiary, Maxin Biological, focuses on core technologies in pathological diagnosis and explores innovative technologies such as companion diagnostics and AI in pathology, aiming for the integrated development of six technical platforms [2]

Core Viewpoint - Beijing Strong Biotechnologies, Inc. (referred to as "the Company") has issued convertible bonds to raise funds for its diversified and high-quality in vitro diagnostic testing platform, with a total fundraising amount of RMB 1.139 billion [3][16]. Section 1: Bond Issuance Details - The Company approved the issuance of convertible bonds on September 6, 2021, and received regulatory approval from the China Securities Regulatory Commission on June 6, 2022 [2][3]. - A total of 11.39 million convertible bonds were issued at a face value of RMB 100 each, raising a gross amount of RMB 113.9 million, with a net amount of RMB 112.685 million after deducting issuance costs [3][4]. Section 2: Financial Performance - For the fiscal year 2024, the Company reported a revenue of RMB 165,893.20 million, a decrease of 4.75% compared to RMB 174,162.67 million in 2023 [21]. - The net profit attributable to shareholders increased by 1.70% to RMB 53,263.53 million from RMB 52,374.28 million in the previous year [22]. - The total assets of the Company grew by 7.71% to RMB 557,496.52 million, while the net assets attributable to shareholders increased by 11.11% to RMB 413,837.41 million [22]. Section 3: Use of Proceeds - The net proceeds from the bond issuance will be allocated to various projects, with a total planned investment of RMB 128.9 million [16][18]. - The Company will self-finance any shortfall if the actual net proceeds are less than the planned investment amount [19]. Section 4: Bondholder Rights and Management - The bondholders have rights to interest payments, conversion to shares, and the ability to sell back their bonds under certain conditions [15][12]. - The Company has established a special account for managing the proceeds from the bond issuance, ensuring that funds are used as intended [23]. Section 5: Credit Rating - The Company has maintained a credit rating of AA- with a stable outlook from Zhongjian Pengyuan Credit Rating Co., Ltd. since November 2021 [20][27].